Title: Virulizin® (Lorus)
CAS Registry Number: 216586-46-8
Additional Names: Virulizin-2g
Literature References: Biological response modifier extracted from bovine bile. Prepn: R. Rang, WO 9507089 (1995 to Imutec); idem, US 6551623 (2003 to Lorus). In vivo antitumor activity: N. Feng et al., Cancer Chemother. Pharmacol. 51, 247 (2003). Clinical evaluation in pancreatic cancer: E. Warner et al., Clin. Invest. Med. 17, 37 (1994). Mechanism of action studies: M. Y. Cao et al., Cancer Immunol. Immunother. 54, 229 (2005); H. Li et al., ibid. 1115. Review of pharmacology and therapeutic potential: E. S. Ferdinandi et al., Expert Opin. Invest. Drugs 8, 1721-1735 (1999).
Properties: Aqueous soln containing 5% (w/v) solid material comprised of a mixture of inorganic salts (95-99% dry wt) and organic compds of mol wts <3000 Da (1-5% dry wt).
Therap-Cat: Immunomodulator.
Keywords: Immunomodulator.

Others monographs:
Calcium CitrateArsenicBoldinePenicillin V
LimoneneAluminum TartrateTibezonium IodideMagnesium Chloride
Manganese AcetateStigmastanolIsomethepteneBismuth Bromide
Indium Arsenide1,4-NaphthoquinoneLatrunculinsMethyl Nonyl Ketone
©2016 DrugLead US FDA&EMEA